Aarti Pharmalabs Limited
NSE: AARTIPHARM · Pharmaceuticals
Snapshot
Unlock Aarti Pharmalabs Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aarti Pharmalabs Limited is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities, and xanthine derivatives. The company operates primarily within the Indian market and was incorporated in 2019.
Business Model
The company generates revenue through the large-scale manufacturing and supply of chemical compounds and pharmaceutical ingredients to various healthcare and industrial clients.
Growth Outlook
Growth is expected to be driven by the expansion of its portfolio in new chemical entities and the scaling of its xanthine derivatives production capabilities.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities, where non-compliance could lead to production halts or product recalls.
- Raw Material Price Volatility. Fluctuations in the costs of key chemical feedstocks and intermediates can significantly impact operating margins.
- Environmental Regulations. As a chemical manufacturer, the company is subject to evolving environmental standards that may necessitate increased capital expenditure for waste management.
- Competitive Pressure. The API and pharmaceutical intermediate market is highly fragmented, leading to intense price competition from both domestic and international players.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Aarti Pharmalabs Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,819 Cr
TTM · consolidated
NET PROFIT
₹186 Cr
TTM · consolidated
EPS
₹20.57
TTM · consolidated
RETURN ON EQUITY
9.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
12.4%
TTM · consolidated
P/E
34.9x
Q4 FY26 · consolidated
EV/EBITDA
18.2x
Q4 FY26 · consolidated
EBITDA MARGIN
21.7%
TTM · consolidated
NET PROFIT MARGIN
10.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Aarti Pharmalabs LimitedAARTIPHARM | 5,745 | 34.88 | 18.20 | -14.0% | 21.7% | 9.2% | 12.4% | -25.7% |
Sudeep PharmaSUDEEPPHRM | 7,043 | — | — | — | 35.0% | — | — | — |
Shilpa Medicare LimitedSHILPAMED | 6,974 | 42.78 | 29.45 | 19.6% | 28.9% | 10.0% | 13.2% | -31.6% |
Blue Jet Healthcare Ltd.BLUEJET | 6,062 | 41.13 | 27.96 | -8.0% | 38.3% | 20.8% | 27.7% | -38.6% |
FDC LimitedFDC | 5,431 | 24.39 | 14.83 | 3.0% | 21.2% | 12.1% | 15.8% | -15.0% |
Supriya Lifescience LimitedSUPRIYA | 4,613 | 32.74 | 22.28 | 18.9% | 36.9% | 20.0% | 25.6% | +18.0% |
As of Q4 FY26
Financials
Aarti Pharmalabs Limited
NSE: AARTIPHARM · Pharmaceuticals
Snapshot
Unlock Aarti Pharmalabs Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aarti Pharmalabs Limited is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities, and xanthine derivatives. The company operates primarily within the Indian market and was incorporated in 2019.
Business Model
The company generates revenue through the large-scale manufacturing and supply of chemical compounds and pharmaceutical ingredients to various healthcare and industrial clients.
Growth Outlook
Growth is expected to be driven by the expansion of its portfolio in new chemical entities and the scaling of its xanthine derivatives production capabilities.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from health authorities, where non-compliance could lead to production halts or product recalls.
- Raw Material Price Volatility. Fluctuations in the costs of key chemical feedstocks and intermediates can significantly impact operating margins.
- Environmental Regulations. As a chemical manufacturer, the company is subject to evolving environmental standards that may necessitate increased capital expenditure for waste management.
- Competitive Pressure. The API and pharmaceutical intermediate market is highly fragmented, leading to intense price competition from both domestic and international players.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Aarti Pharmalabs Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,819 Cr
TTM · consolidated
NET PROFIT
₹186 Cr
TTM · consolidated
EPS
₹20.57
TTM · consolidated
RETURN ON EQUITY
9.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
12.4%
TTM · consolidated
P/E
34.9x
Q4 FY26 · consolidated
EV/EBITDA
18.2x
Q4 FY26 · consolidated
EBITDA MARGIN
21.7%
TTM · consolidated
NET PROFIT MARGIN
10.5%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26